E

Editas Medicine
D

EDIT

1.51000
USD
-0.11
(-6.79%)
مفتوح الان
حجم التداول
17,707
الربح لكل سهم
-2
العائد الربحي
-
P/E
-0
حجم السوق
126,406,417
أصول ذات صلة
ALNY
ALNY
-2.57
(-0.89%)
286.78 USD
B
BEAM
-0.540
(-3.13%)
16.710 USD
C
CRSP
-0.755
(-2.01%)
36.855 USD
N
NTLA
-0.38500
(-4.06%)
9.09000 USD
REGN
REGN
-8.82
(-1.48%)
587.83 USD
S
SRPT
-0.880
(-2.27%)
37.920 USD
TMO
TMO
-5.92
(-1.48%)
393.99 USD
VRTX
VRTX
1.80
(0.41%)
435.33 USD
المزيد
الأخبار المقالات

العنوان: Editas Medicine

القطاع: Healthcare
الصناعة: Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.